ZNF112

Summary

ZNF112 (zinc finger protein 112, HGNC:12892) is a protein-coding gene on chromosome 19q13.31, encoding Zinc finger protein 112 (Q9UJU3). May be involved in transcriptional regulation.

Predicted to enable DNA binding activity and zinc ion binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.

Source: NCBI Gene 7771 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (No Known Disease Relationship, GenCC)
• Clinical variants (ClinVar): 116 total
• MANE Select transcript: NM_013380

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12892
Approved symbol	ZNF112
Name	zinc finger protein 112
Location	19q13.31
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000062370
Ensembl biotype	protein_coding
OMIM	603994
Entrez	7771

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 8 protein_coding, 1 nonsense_mediated_decay

ENST00000337401, ENST00000354340, ENST00000587909, ENST00000588057, ENST00000590687, ENST00000592151, ENST00000911245, ENST00000911246, ENST00000911247

RefSeq mRNA: 7 — MANE Select: NM_013380 NM_001083335, NM_001348281, NM_001348282, NM_001348283, NM_001348284, NM_001348285, NM_013380

CCDS: CCDS12637, CCDS54276

Canonical transcript exons

ENST00000354340 — 4 exons

Exon	Start	End
ENSE00001246068	44326555	44329936
ENSE00002830968	44356626	44356680
ENSE00003594914	44336623	44336718
ENSE00003681910	44340416	44340542

Expression profiles

Bgee: expression breadth ubiquitous, 248 present calls, max score 82.96.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.3967 / max 44.3196, expressed in 1121 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
181390	2.1427	1045
181391	0.2024	89
181389	0.0516	15

Top tissues by expression

276 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
germinal epithelium of ovary	UBERON:0001304	82.96	gold quality
cortical plate	UBERON:0005343	82.77	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.87	gold quality
ganglionic eminence	UBERON:0004023	80.58	gold quality
calcaneal tendon	UBERON:0003701	80.38	gold quality
parietal pleura	UBERON:0002400	79.49	gold quality
hair follicle	UBERON:0002073	78.12	silver quality
tibia	UBERON:0000979	78.03	gold quality
pleura	UBERON:0000977	77.73	gold quality
ventricular zone	UBERON:0003053	77.35	gold quality
visceral pleura	UBERON:0002401	77.06	gold quality
stromal cell of endometrium	CL:0002255	75.90	gold quality
cerebellar hemisphere	UBERON:0002245	75.89	gold quality
cerebellar cortex	UBERON:0002129	75.74	gold quality
right hemisphere of cerebellum	UBERON:0014890	75.18	gold quality
sperm	CL:0000019	74.86	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	74.84	gold quality
cerebellum	UBERON:0002037	74.70	gold quality
adrenal tissue	UBERON:0018303	74.41	gold quality
palpebral conjunctiva	UBERON:0001812	74.19	gold quality
embryo	UBERON:0000922	73.56	gold quality
right adrenal gland cortex	UBERON:0035827	73.38	gold quality
epithelial cell of pancreas	CL:0000083	73.27	silver quality
C1 segment of cervical spinal cord	UBERON:0006469	73.26	gold quality
islet of Langerhans	UBERON:0000006	72.98	gold quality
right adrenal gland	UBERON:0001233	72.94	gold quality
male germ cell	CL:0000015	72.86	silver quality
left adrenal gland	UBERON:0001234	72.48	gold quality
lower esophagus	UBERON:0013473	72.29	gold quality
lower esophagus muscularis layer	UBERON:0035833	72.29	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-7249	no	74.37
E-ANND-3	no	3.64

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): STAT1

miRNA regulators (miRDB)

55 targeting ZNF112, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-148A-5P	99.30	68.27	1141

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp112	ENSMUSG00000052675
rattus_norvegicus	Zfp112	ENSRNOG00000029022

Paralogs (176): ZNF195 (ENSG00000005801), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631), ZNF3 (ENSG00000166526)

Protein

Protein identifiers

Zinc finger protein 112 — Q9UJU3 (reviewed: Q9UJU3)

Alternative names: Zinc finger protein 228

All UniProt accessions (5): Q9UJU3, K7EIR6, K7EN57, K7ENS0, K7EQV5

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UJU3-1	1	yes
Q9UJU3-2	2

RefSeq proteins (7): NP_001076804, NP_001335210, NP_001335211, NP_001335212, NP_001335213, NP_001335214, NP_037512* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (36 total): zinc finger region 17, sequence variant 7, sequence conflict 7, cross-link 2, chain 1, domain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UJU3-F1	55.13	0.07

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 256, 890

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 79 (showing top): BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, STAT3_01, GGAMTNNNNNTCCY_UNKNOWN, KOYAMA_SEMA3B_TARGETS_UP, DODD_NASOPHARYNGEAL_CARCINOMA_UP, CHEN_HOXA5_TARGETS_9HR_UP, GOCC_NUCLEOLUS, SCGGAAGY_ELK1_02, STAT5A_01, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, HUTTMANN_B_CLL_POOR_SURVIVAL_UP, MIKKELSEN_ES_ICP_WITH_H3K4ME3, MIKKELSEN_NPC_ICP_WITH_H3K4ME3, VERHAAK_GLIOBLASTOMA_CLASSICAL, GOCC_FIBRILLAR_CENTER

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (3): DNA binding (GO:0003677), zinc ion binding (GO:0008270), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
nucleic acid binding	1
transition metal ion binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

240 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF112	FGFR1OP2	Q9NVK5	641
ZNF112	ZMYM2	Q9UBW7	630
ZNF112	RPL13	P26373	582
ZNF112	CNTRL	Q7Z7A1	527
ZNF112	MANBAL	Q9NQG1	403
ZNF112	TMEM123	Q8N131	376
ZNF112	GRWD1	Q9BQ67	323
ZNF112	CEACAM19	Q7Z692	306
ZNF112	ADAMTS19	Q8TE59	293
ZNF112	HS3ST3B1	Q9Y662	278
ZNF112	FGFR1	P11362	266
ZNF112	WWC1	Q8IX03	266
ZNF112	STMN4	Q9H169	256
ZNF112	FAM111A	Q96PZ2	253
ZNF112	UACA	Q9BZF9	248

IntAct

8 interactions, top by confidence:

A	B	Type	Score
TRIM28	ZNF320	psi-mi:“MI:0914”(association)	0.530
CFTR	ZNF112	psi-mi:“MI:0915”(physical association)	0.370
ZNF112	ECE1	psi-mi:“MI:0915”(physical association)	0.370
ZNF284	DIAPH1	psi-mi:“MI:0914”(association)	0.350
ZNF112	TRIM28	psi-mi:“MI:0914”(association)	0.350
NDEL1	ZNF112	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (12): ZNF112 (Affinity Capture-MS), ZNF112 (Proximity Label-MS), ZNF112 (Proximity Label-MS), ZNF235 (Affinity Capture-MS), TRIM28 (Affinity Capture-MS), TRIM39 (Affinity Capture-MS), ZNF112 (Affinity Capture-MS), HAUS4 (Affinity Capture-MS), ZNF112 (Affinity Capture-MS), ZNF112 (Affinity Capture-MS), ZNF112 (PCA), ZNF112 (Affinity Capture-MS)

ESM2 similar proteins: A0JPL0, A6NK53, E7ETH6, E9Q8G5, O14628, P21506, P51508, Q09FC8, Q13360, Q2M218, Q2M3X9, Q2VY69, Q3KQV3, Q3SY52, Q4R882, Q5HY98, Q5REN4, Q5RES8, Q68DI1, Q6NX49, Q6P280, Q6PG37, Q6V9R5, Q6ZMW2, Q7Z340, Q86XU0, Q8IYI8, Q8N587, Q8N720, Q8N859, Q8NB42, Q8NDW4, Q8NEK5, Q8WXB4, Q96MR9, Q96MU6, Q96NG8, Q96NJ3, Q96SR6, Q9BR84

Diamond homologs: A0A1W2PQL4, A0JNB1, A0JPL0, A6NK53, A6QLU5, A6QPT6, A7MBI1, A8MT65, A8MUV8, A8MWA4, B2RXC5, B4DU55, B4DX44, E9PYI1, O14628, O75346, P0CH99, P0CI00, P17014, P17030, P17032, P17098, P51786, P85977, Q02386, Q06730, Q06732, Q0VAW7, Q12901, Q13360, Q14586, Q14588, Q14590, Q16587, Q2M3X9, Q2VY69, Q32M78, Q3ZCX4, Q49AA0, Q4R6J4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

116 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	108
Likely benign	6
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

972 predictions. Top by Δscore:

Variant	Effect	Δscore
19:44336715:TGTG:T	acceptor_gain	1.0000
19:44336716:GTG:G	acceptor_gain	1.0000
19:44336718:GC:G	acceptor_loss	1.0000
19:44336719:C:CC	acceptor_gain	1.0000
19:44336719:CTGTA:C	acceptor_loss	1.0000
19:44340408:AT:A	donor_gain	1.0000
19:44340410:CCTCA:C	donor_loss	1.0000
19:44340411:CTCAC:C	donor_loss	1.0000
19:44340412:TCA:T	donor_loss	1.0000
19:44340413:CA:C	donor_loss	1.0000
19:44340414:A:C	donor_loss	1.0000
19:44340415:C:G	donor_loss	1.0000
19:44340415:CCTA:C	donor_gain	1.0000
19:44340418:A:AC	donor_gain	1.0000
19:44340419:C:CC	donor_gain	1.0000
19:44340431:T:TA	donor_gain	1.0000
19:44355771:ATG:A	donor_gain	1.0000
19:44355771:ATGC:A	donor_gain	1.0000
19:44355784:C:CA	donor_gain	1.0000
19:44336617:TCTCA:T	donor_loss	0.9900
19:44336618:CTCAC:C	donor_loss	0.9900
19:44336619:TCA:T	donor_loss	0.9900
19:44336620:CA:C	donor_loss	0.9900
19:44336622:C:A	donor_loss	0.9900
19:44336622:C:CA	donor_loss	0.9900
19:44336714:ATGTG:A	acceptor_gain	0.9900
19:44336717:TG:T	acceptor_gain	0.9900
19:44336721:G:C	acceptor_gain	0.9900
19:44336721:G:GC	acceptor_gain	0.9900
19:44340540:CTC:C	acceptor_gain	0.9900

AlphaMissense

6103 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:44327649:G:C	F842L	0.999
19:44327649:G:T	F842L	0.999
19:44327651:A:G	F842L	0.999
19:44328153:G:C	F674L	0.999
19:44328153:G:T	F674L	0.999
19:44328155:A:G	F674L	0.999
19:44328237:G:C	F646L	0.999
19:44328237:G:T	F646L	0.999
19:44328239:A:G	F646L	0.999
19:44328321:G:C	F618L	0.999
19:44328321:G:T	F618L	0.999
19:44328323:A:G	F618L	0.999
19:44327565:G:C	F870L	0.998
19:44327565:G:T	F870L	0.998
19:44327567:A:G	F870L	0.998
19:44327650:A:G	F842S	0.998
19:44327733:G:C	F814L	0.998
19:44327733:G:T	F814L	0.998
19:44327735:A:G	F814L	0.998
19:44327985:G:C	F730L	0.998
19:44327985:G:T	F730L	0.998
19:44327987:A:G	F730L	0.998
19:44328322:A:G	F618S	0.998
19:44328405:G:C	F590L	0.998
19:44328405:G:T	F590L	0.998
19:44328407:A:G	F590L	0.998
19:44328489:G:C	F562L	0.998
19:44328489:G:T	F562L	0.998
19:44328491:A:G	F562L	0.998
19:44327901:A:C	F758L	0.997

dbSNP variants (sampled 300 via entrez): RS1000081258 (19:44348178 T>G), RS1000194691 (19:44342843 A>T), RS1000239896 (19:44335097 G>A), RS1000386427 (19:44328795 G>A), RS1000420247 (19:44349615 A>C), RS1000632917 (19:44343006 T>C), RS1000708063 (19:44335928 A>C), RS1000807456 (19:44353559 C>G), RS1000841152 (19:44335490 A>T), RS1000861285 (19:44354585 G>T), RS1000868003 (19:44353294 A>C), RS1000896428 (19:44346344 T>C), RS1000916369 (19:44329954 A>T), RS1001119604 (19:44332915 A>C), RS1001379257 (19:44342040 C>A)

Disease associations

OMIM: gene MIM:603994 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	No Known Disease Relationship	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation	3
TAK-243	increases sumoylation	1
methylmercuric chloride	decreases expression	1
sodium arsenite	decreases expression	1
coumarin	decreases phosphorylation	1
avobenzone	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
Temozolomide	affects response to substance	1
Vorinostat	increases expression	1
Leflunomide	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Atrazine	decreases expression	1
Carmustine	affects response to substance	1
Formaldehyde	decreases expression	1
Quercetin	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	increases expression	1
Urethane	affects expression	1
Okadaic Acid	decreases expression	1
Copper Sulfate	increases expression	1
Particulate Matter	decreases expression, increases abundance	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_XW02	HEK293 eGFP-ZNF112	Transformed cell line	Female

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome